Previous 10 | Next 10 |
(NewsDirect) Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive after the company received clearance from the US Food and Drug Administration (FDA) to begin the Phase 2/3 clinical trial for its IHL-42X asset, designed to address obstruc...
(NewsDirect) Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackley tells Proactive the company has completed a constructive pre-Investigational New Drug (IND) application meeting with the US Food and Drug Administration (FDA) for its IHL-675A proprietary dr...
(NewsDirect) Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has engaged Fortrea as the contract research organisation (CRO) to manage the IND opening Phase 2/3 clinical trial investigating the company’s IHL-42X for the treatment of Obstructiv...
(NewsDirect) Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun the process of shifting all outstanding shares to the Nasdaq after making the decision to redomicile to the United States via a scheme of arrangement. He says the move wil...
(NewsDirect) Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X, a treatment for obstructive sleep apnoea (OSA). The investigators, Dr John D H...
(NewsDirect) Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) director Peter Widdows tells Proactive the company has appointed three world-renowned psychedelic therapy and science experts to its Clarion Clinics Group Advisory Board. The Clarion Clinics Groups Pty Ltd is a collaborative venture ...
(NewsDirect) Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics and the safety of the company’s anti-inflammatory drug candidate IHL-675A...
2023-05-02 16:23:54 ET Summary IIM and IQI are leveraged municipal bond closed-end funds. This leverage meant sharper downside moves when rates were rising, but it could also mean sharper upside moves if rates reverse lower. This is a continuation of looking at muni funds more...
2023-05-01 12:45:40 ET Invesco Quality Municipal Income Trust ( NYSE: IQI ) declares $0.0372/share monthly dividend , in line with previous. Forward yield 4.64% Payable May 31; for shareholders of record May 15; ex-div May 12. See IQI Dividend Scorecard, Yiel...
2023-04-03 13:51:45 ET Invesco Quality Municipal Income Trust ( NYSE: IQI ) declared $0.0372/share monthly dividend , -3.4% decrease from prior dividend of $0.0385. Forward yield 4.52% Payable April 28; for shareholders of record April 17; ex-div April 14. ...
News, Short Squeeze, Breakout and More Instantly...
Invesco Quality Municipal Income Trust Company Name:
IQI Stock Symbol:
NYSE Market:
2024-05-12 00:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-02 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-23 14:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...